Median PFS increased from 1.94 months with single-agent fulvestrant to 5.32 months with the addition of ipatasertib. Patients ...

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- Addition of an investigational AKT inhibitor to standard fulvestrant (Faslodex) doubled median ...

Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Perspective from Stephanie Graff, MD Capivasertib (AZD5363, AstraZeneca) — an investigational AKT inhibitor — also appeared safe and exhibited a manageable toxicity profile, findings of the ...

Barcelona, Spain: In a trial matching new treatments to cancer patients based on the genetic make-up of their tumours, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their ...

Credit: Getty Images. Capivasertib is a potential first-in-class AKT inhibitor. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ...

The AKT inhibitor afuresertib failed to improve progression-free survival (PFS) when added to paclitaxel for patients with heavily treated advanced disease. An exploratory analysis suggested a ...

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a more restrictive label ...

Inavolisib is one of a growing class of inhibitors targeting the PI3K/Akt pathway in certain patients with advanced or metastatic breast cancer. Targeting the pathway, however, has consequences.